West Pharmaceutical Services WST Purchase Price Adjustments

Purchase Price Adjustments at other companies

Halozyme TherapeuticsHALO

——

Proprietary Products-$600K—

Contract-Manufactured Products$0—

Revenue$844.9M+21.0%

Gross profit$296.4M+27.8%

Operating income$177.1M+65.5%

Net income$138.8M+54.6%

EPS (diluted)$1.92+56.1%

Cash & equivalents$521.4M+29.0%

Total debt$321.0M+4.4%

Total equity$3.0B+11.5%

Total assets$4.1B+13.6%

Operating cash flow$89.9M-30.5%

CapEx$42.7M-40.1%

Free cash flow$47.2M-18.8%

Market cap$25.36B+64.2%

Enterprise value$25.16B+65.1%

P/E46.7×+15.1×

P/S7.9×+2.7×

Gross margin36.3%+1.7pp

Operating margin20.3%+1.2pp

Net margin16.8%+0.7pp

FCF margin14.2%+3.6pp

Return on equity19.1%+1.7pp

Debt / equity0.1×0.0×

Current ratio2.7×-0.1×